Diplomat Pharmacy, Inc. (NYSE:DPLO) updated its FY17 earnings guidance on Monday. The company provided EPS guidance of $0.71-0.79 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.65. The company issued revenue guidance of $4.3-4.6 billion, compared to the consensus revenue estimate of $4.57 billion.

Several equities analysts have recently commented on the stock. Bank of America Corporation boosted their price target on shares of Diplomat Pharmacy from $17.00 to $18.50 and gave the company a neutral rating in a report on Thursday, May 25th. BidaskClub cut shares of Diplomat Pharmacy from a hold rating to a sell rating in a report on Monday, July 31st. Cowen and Company boosted their price target on shares of Diplomat Pharmacy from $12.00 to $17.00 and gave the company a market perform rating in a report on Tuesday, May 9th. Needham & Company LLC assumed coverage on shares of Diplomat Pharmacy in a report on Friday, July 21st. They set a buy rating and a $19.75 price target on the stock. Finally, Zacks Investment Research cut shares of Diplomat Pharmacy from a hold rating to a sell rating in a report on Monday, July 17th. Four equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and two have issued a buy rating to the company’s stock. The company has an average rating of Hold and an average target price of $20.91.

Shares of Diplomat Pharmacy, Inc. (DPLO) opened at 16.60 on Wednesday. The company has a 50-day moving average of $15.76 and a 200-day moving average of $15.65. Diplomat Pharmacy, Inc. has a one year low of $12.25 and a one year high of $37.83. The company has a market capitalization of $1.11 billion, a PE ratio of 66.14 and a beta of 0.66.

Diplomat Pharmacy (NYSE:DPLO) last released its earnings results on Monday, August 7th. The company reported $0.25 earnings per share for the quarter, beating analysts’ consensus estimates of $0.15 by $0.10. The business had revenue of $1.13 billion during the quarter, compared to the consensus estimate of $1.14 billion. Diplomat Pharmacy had a net margin of 0.27% and a return on equity of 8.03%. The firm’s revenue for the quarter was up 3.5% compared to the same quarter last year. During the same quarter last year, the firm earned $0.23 earnings per share. On average, analysts anticipate that Diplomat Pharmacy, Inc. will post $0.74 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another publication, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this news story can be viewed at https://www.dailypolitical.com/2017/08/09/diplomat-pharmacy-inc-nysedplo-issues-fy17-earnings-guidance.html.

About Diplomat Pharmacy

Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.

Receive News & Ratings for Diplomat Pharmacy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc. and related companies with MarketBeat.com's FREE daily email newsletter.